IXICO plc Extension of Huntington's disease consortium (1157V)

TIDMIXI

RNS Number : 1157V

IXICO plc

03 April 2023

3 April 2023

IXICO plc

("IXICO" or the "Company")

Extension of Huntington's disease consortium worth circa GBP1 million

IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has secured additional contract orders to support completion of the retrospective analysis of over 6,000 HD imaging datasets through the Huntington's Disease Imaging Harmonization Consortium (HD-IH), previously announced on 21(st) September 2022. HD is a rare, inherited neurodegenerative disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities. There are no existing approved disease modifying therapies for HD, nor interventions that slow disease progression.

The output of the project will enable current and prospective consortium partners together with their collaborators to develop improved approaches to stratifying patients in HD clinical trials as well as increasing the precision of efficacy measurements of drugs within HD clinical trials. IXICO is delivering this analysis to the biopharma and charitable foundation consortium members using its proprietary, deep learning based, IXIQ.Ai analysis platform. Additional financial contribution has been secured from two partners, where one is a new consortium member and the other, an existing consortium member, enabling completion by June 2025. The consortium partners remain open for additional partners to join to benefit from the analysis already undertaken and to further accelerate completion of the project.

Giulio Cerroni, Chief Executive Officer of IXICO, commented : " The HD-IH consortium is working on the development of new standards for imaging in HD through the analysis and interpretation of existing HD imaging datasets. We are very excited to build additional momentum in the consortium and look forward to working closely with our existing and new partners towards the development of novel imaging tools that enable the design of more efficient HD clinical trials.

The development of new imaging standards in this consortium further cements IXICO's position as the leading analysis company for HD as part of its wider portfolio of leading analytical tools to support clinical trials into neurological diseases."

For further information please contact:

 
 IXICO plc                                              [phone] 
 Giulio Cerroni, Chief Executive 
  Officer 
  Grant Nash, Chief Financial Officer 
 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                      [phone] 
 Giles Balleny / Max Gould (Corporate 
  Finance) 
 Michael F Johnson / Tamar Cranford-Smith 
  (Sales) 
 
 
 

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough machine learning Ai data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTSSESWDEDSEDL

(END) Dow Jones Newswires

April 03, 2023 03:35 ET (07:35 GMT)